HRT vs bisphosphonates for osteoporosis: key differences

Hormone replacement therapy (HRT) and bisphosphonates both reduce fracture risk in postmenopausal women, but they work through entirely different mechanisms and carry very different safety profiles. HRT replaces estrogen lost at menopause, which slows the bone breakdown process; bisphosphonates like alendronate and risedronate bind directly to bone and block the cells that resorb it. For most women whose only concern is bone protection, bisphosphonates are now the standard first choice. HRT remains an option when bone loss coincides with significant menopausal symptoms — hot flashes, sleep disruption, mood changes — where one treatment can address both problems at once.

This explainer draws on peer-reviewed research from four rheumatologists listed in the Convene directory whose published work covers the full bisphosphonate treatment evidence base, anabolic alternatives, and the evolution of osteoporosis pharmacotherapy.

How each treatment works

Your bones are not static. Throughout your life, old bone is constantly broken down by cells called osteoclasts, and new bone is built by cells called osteoblasts. In healthy bone, these processes stay in balance. After menopause, estrogen levels drop sharply, and that balance tips: osteoclasts become more active, bone is lost faster than it is replaced, and density falls.

HRT corrects this imbalance by restoring estrogen. With more estrogen circulating, osteoclast activity is held in check and bone loss slows. The bone-protective effect is real and well-documented, though it was largely set aside after a 2002 landmark trial raised concerns about breast cancer and cardiovascular events in older women on combined estrogen-progestin therapy.

Bisphosphonates take a different approach. They bind tightly to the mineral surface of bone, especially in areas with high remodeling activity. When an osteoclast tries to resorb that bone, it absorbs the bisphosphonate and is destroyed. The result is a direct reduction in bone breakdown. Trial data for alendronate — the most studied bisphosphonate — showed that it increases bone mineral density in patients losing bone due to glucocorticoid therapy [1], with benefits sustained over two years [2]. A 2009 HORIZON trial published in The Lancet showed that zoledronic acid (given once yearly by infusion) outperformed oral risedronate in preventing bone loss in patients on glucocorticoids [3].

At a glance

When bisphosphonates are the standard choice

For women over 60, or those who have no menopausal symptoms but do have documented bone loss or fracture risk, bisphosphonates are generally the recommended starting point. They have no systemic hormone effects and their fracture-reduction data is extensive.

Alendronate established this track record in randomized controlled trials that are now more than two decades old. The original NEJM trial by Kenneth Saag and colleagues showed meaningful bone density gains in patients on glucocorticoids — a population with accelerated bone loss — and those gains held in a two-year extension [1][2]. The HORIZON trial later confirmed that zoledronic acid, given as a single annual infusion, could outperform oral risedronate in the same high-risk patient group [3].

Risedronate is another well-studied option. A 2009 trial published in Clinical Interventions in Aging found that risedronate 150 mg once monthly was as effective as the standard weekly dose and was better tolerated in some patients [14] — a meaningful practical advantage since many people struggle with the rigid once-weekly fasting requirement of oral bisphosphonates.

The biggest practical drawback of oral bisphosphonates is that they require careful dosing: you take the pill first thing in the morning, on an empty stomach, with a full glass of water, and stay upright for at least 30 minutes. Skipping any step significantly reduces absorption and increases the risk of esophageal irritation. For patients who cannot follow that protocol reliably, or who have significant GERD, the annual zoledronic acid infusion avoids all of that.

When HRT makes sense for bone health

HRT is not the first-line bone protection option for most women, but it is not obsolete either. Two situations where your doctor might consider it:

You are under 60, recently menopausal, and dealing with significant symptoms. If hot flashes or sleep disruption are already disrupting your life, starting HRT makes more sense than adding a bisphosphonate on top of menopause treatment you were going to need anyway. The bone-protective effect comes with the package.

You cannot tolerate bisphosphonates. Some patients have severe GI side effects from oral bisphosphonates and are not candidates for IV zoledronic acid. For this group, HRT or other alternatives become more relevant.

The estrogen dose needed for bone protection is relatively low — lower than what was used in the large trials that raised cancer and cardiovascular concerns. Current guidance from most medical societies says that in healthy women under 60 who are within 10 years of menopause, the benefits of HRT for both symptoms and bone protection generally outweigh the risks. That calculation shifts for older women or those with personal or family history of hormone-sensitive cancers.

What the newer data shows about alternatives

Bisphosphonates are not the only antiresorptive option anymore. Denosumab, a monoclonal antibody, works through a completely different mechanism: it blocks a protein (RANKL) that signals osteoclasts to activate. A head-to-head phase 3 trial found that denosumab produced greater increases in bone mineral density than alendronate in postmenopausal women with low bone mass [6]. For patients who cannot take oral bisphosphonates and prefer a twice-yearly injection over an annual IV infusion, denosumab is a reasonable alternative. Research by Robin Dore also looked at denosumab in rheumatoid arthritis patients already taking bisphosphonates, and found that adding denosumab produced further BMD improvement even in that pretreated group [10].

On the anabolic side — drugs that build bone rather than just slow its loss — teriparatide (a synthetic form of parathyroid hormone) has strong data. A 2002 randomized trial found that teriparatide outperformed alendronate in postmenopausal women with osteoporosis for spinal bone mineral density gains [9]. A 2007 NEJM trial by Kenneth Saag and colleagues found the same advantage in glucocorticoid-induced osteoporosis: patients on teriparatide gained more bone than those on alendronate [4]. A meta-analysis of teriparatide trials also found a reduced risk of back pain in patients treated with it [17], which matters given that vertebral fractures are often what bring osteoporosis to clinical attention in the first place.

The most recent chapter is romosozumab, an antibody that both builds new bone and slows bone loss simultaneously. A 2017 NEJM trial found that a year of romosozumab followed by alendronate reduced fracture risk more than alendronate alone in high-risk postmenopausal women [5]. However, the trial also found a signal for cardiovascular events, and romosozumab is now contraindicated in patients with recent heart attack or stroke.

Chad Deal and colleagues explored the combination of teriparatide with raloxifene — a selective estrogen receptor modulator that provides some estrogen-like bone protection without stimulating breast or uterine tissue. A six-month double-blind trial found that the combination did not clearly outperform either drug alone [7], suggesting that stacking anabolic and antiresorptive therapies requires careful timing to be effective.

When bone loss happens due to steroids

Glucocorticoid-induced osteoporosis deserves specific mention because it affects a large number of people who take prednisone or other steroids long-term for conditions like rheumatoid arthritis, inflammatory bowel disease, or asthma. This type of bone loss happens fast — significant density can be lost within the first few months of steroid therapy. Paula Rackoff wrote about the underlying biology in a 1998 paper: glucocorticoids suppress osteoblast function and accelerate osteoclast activity simultaneously, which is why the bone loss is more rapid than in typical postmenopausal osteoporosis [13].

For this group, HRT alone is rarely sufficient. Alendronate has strong evidence specifically in glucocorticoid users [1][2], and teriparatide outperformed alendronate in a head-to-head trial in this same population [4]. Current guidelines recommend starting bone protection early — often at the same time as the steroid therapy, rather than waiting for bone density to fall.

Stopping either treatment: what happens next

Both HRT and bisphosphonates lose their protective effect when you stop taking them, but the timelines differ.

With HRT, bone loss typically resumes within a year of stopping — sometimes faster. If you stop HRT, your doctor will likely arrange a bone density scan within 12 to 18 months to assess whether additional treatment is needed.

Oral bisphosphonates bind so tightly to bone mineral that they persist in bone tissue for years after you stop taking them, providing some continued fracture protection. This is the basis for the "drug holiday" — the practice of stopping oral bisphosphonates after three to five years in lower-risk patients and monitoring without treatment for a period. Zoledronic acid behaves similarly. The key point is that a planned drug holiday is different from simply stopping: it involves a reassessment of your fracture risk profile and a plan for when to restart.

Questions to ask your doctor

• Do I have enough bone loss or fracture risk to need medication now, or is lifestyle modification (calcium, vitamin D, weight-bearing exercise) enough at this stage?
• If I am also dealing with significant menopausal symptoms, does it make sense to address both with HRT rather than taking two separate medications?
• Given my GI history and lifestyle, can I reliably take an oral bisphosphonate correctly, or should we consider an injectable or infusion option?
• Have I been on a bisphosphonate long enough that a drug holiday is worth discussing?
• If I am on long-term steroids, what bone protection should I start now — and at what dose threshold does that become necessary?
• Are there reasons I should consider an anabolic therapy (teriparatide, romosozumab) instead of an antiresorptive like a bisphosphonate?

The bottom line

For most postmenopausal women who need treatment for bone loss, bisphosphonates are the standard starting point. They have decades of fracture data, are available as inexpensive generics, and do not carry the systemic hormone effects of HRT. HRT remains a reasonable option when both menopausal symptoms and bone protection are needed together, particularly in women who are younger and recently menopausal. Beyond these two categories, newer agents — denosumab, teriparatide, romosozumab — fill specific niches depending on fracture risk level, steroid use, prior treatment, and cardiovascular history. The choice is not one-size-fits-all, and the evidence base for matching the right drug to the right patient has grown substantially.